

# Lutz Wollin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4127809/publications.pdf>

Version: 2024-02-01

9  
papers

1,700  
citations

1040056

9  
h-index

1474206

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

2309  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Nintedanib in an Animal Model of Liver Fibrosis. <i>BioMed Research International</i> , 2020, 2020, 1-9.	1.9	19
2	TNF- $\alpha$ and IL-10 Control CXCL13 Expression in Human Macrophages. <i>Journal of Immunology</i> , 2020, 204, 2492-2502.	0.8	34
3	Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 212-218.	1.7	31
4	Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib. <i>International Immunopharmacology</i> , 2019, 72, 112-123.	3.8	38
5	Effects of nintedanib on the microvascular architecture in a lung fibrosis model. <i>Angiogenesis</i> , 2017, 20, 359-372.	7.2	107
6	Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1941-1948.	0.9	149
7	Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 883-890.	0.9	154
8	Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2015, 45, 1434-1445.	6.7	667
9	Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 349, 209-220.	2.5	501